Imunon, Inc. (NASDAQ:IMNN), a pharmaceutical preparations company currently trading at $1.32 with a market capitalization of $29.2 million, has regained compliance with Nasdaq’s minimum bid ...

Imunon, Inc. (NASDAQ:IMNN), a pharmaceutical preparations company currently trading at $1.32 with a market capitalization of $29.2 million, has regained compliance with Nasdaq’s minimum bid price ...

LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy ...

IMUNON’s TheraPlas is a non-viral delivery system that can support development of a range of immunotherapies and other anti-cancer nucleic acid-based therapies. For example, using this advanced ...

IMUNON presented translational data from its OVATION 2 Phase 2 study of IMNN-001, a DNA-based IL-12 immunotherapy for advanced ovarian cancer. The therapy showed dose-dependent increases in IL-12 ...

At close: June 9 at 4:00:01 PM EDT ...

As diagnoses climb and innovation accelerates, major federal funding cuts are forcing a shift toward private biotech - and ...

Stitch Fix reported quarterly losses of six cents per share, which beat the analyst consensus estimate of losses of 11 cents per share. Quarterly revenue came in at $325.02 million, beating the ...